Markets

This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month

Reported by MarketWatch · Published 22 Sep 2026, 11:46 PM MYT (3 hr ago)

Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.

Source & full coverage: this summary is aggregated from MarketWatch, the original publisher. Read the complete report for full context, data and quotes.

Read the original report at MarketWatch →

This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month

Summary

More in Markets

She was ready to buy her dream condo — but discovered the HOA had just 1% in cash reserves

Should you apply for multiple credit cards at once?

Defending against dangerous AI should be a national priority — and we need more AI to do it

Quantum stocks are getting hot again after a brutal summer. Can the rally last?

Binance takes $100M stake in Circle to boost USDC

Herc Holdings Inc. (HRI) Was Gabelli Focused Growth and Income Fund’s Top Q2 Contributor